Trial Profile

Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Therapeutic Use

Most Recent Events

09 Apr 2024 Planned End Date changed from 1 Aug 2028 to 1 Aug 2029.
09 Apr 2024 Planned primary completion date changed from 5 Apr 2024 to 5 Apr 2025.
06 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 5 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com